OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) - Opportunity Analysis and Forecasts to 2017

The idiopathic pulmonary fibrosis (IPF) therapy market across the US and EU will surpass $1 billion by 2017, and pharma companies could stand to benefit handsomely if they can add to the limited knowledge of the disease, states new analysis. For more information visit: OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) - Opportunity Analysis and Forecasts to 2017

The new research, "OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) - Opportunity Analysis and Forecasts to 2017", states that over 70,000 people in the US and EU are thought to suffer from IPF, representing a commercially attractive patient population size with a financially appealing orphan drug status. So why has IPF been overlooked by the healthcare industry until the last decade?

Dr. Samantha Fernando, the report analyst covering Immunology, explains: “Future R&D strategies require the identification of critical biomarkers, so that disease progression and treatment response can be tracked – imperative to this is investment in research. The majority of existing knowledge on IPF has been captured by academics, and collaboration between academics and pharmaceutical companies is key to the advancement of this developing market. However, increased regulatory rigidness and extended trial duration is essential for this progressive disease, making drug development difficult. Approved medications also face a challenging economy, as increased emphasis is placed on the cost-effectiveness of drugs, particularly in the EU where various austerity measures are in place.”

The severely underserved market currently only has one licensed pharmacological treatment, InterMune’s Esbriet, an immunosuppressant with dual anti-fibrotic and anti-inflammatory properties licensed for use by the European Medicines Agency in 2011. However, despite being an orphan drug, it is not readily available across the region, due to its exorbitant price (>€22,000) relative to small therapeutic effect.

Analyst of this report expects IPF therapy sales across the US, France, Germany, Italy, Spain, and the UK to rise from $49m in 2012 to over $1.1 billion by 2017, at a Compound Annual Growth Rate (CAGR) of 86.6%. The EU has so far dominated the IPF market, but the US is set to reclaim market share in the future.

The IPF therapeutics market in the US is predicted to grow from a value of $6.5m in 2012 to $696m in 2017, at a Compound Annual Growth Rate (CAGR) of 154%. Dr. Fernando notes: “The anticipated launch of Esbriet and Nintedanib in 2015, to a market that previously had no therapeutic option will cause the US market to experience exponential growth, reaching nearly $500m in 2015 from only $19m in 2014. In contrast, the European IPF market was valued at a far stronger $43m in 2012, but is forecast to grow to $419m in 2017 at a CAGR of 58%.”

Spanning over 136 pages, 32 tables and 13 figures, “OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) - Opportunity Analysis and Forecasts to 2017” report develop business strategies by understanding the trends shaping and driving the global IPF therapeutics market.

In addition to covering the Disease Overview, Epidemiology, Current Treatment Options, Unmet Needs Assessment and Oppportunity Analysis, R&D Strategies and Pipeline Assessment, the report also presents pipeline valuation analysis for the Idiopathic Pulmonary Fibrosis (IPF). Browse more Pharma and Healthcare market research reports.

Hospital Market in India 2013

Indian hospital market faces a critical crunch in the number of hospital beds in comparison to the demand it faces. The hospital market in India has strong growth potential that is characterized by continual possibility of growth. Persistent growth in population necessitates the growth in both public as well as private hospital facilities to cater to population of varied economic standards residing in the country. For more information visit: Hospital Market in India 2013

A gradual trend is being observed in terms of demand for quality healthcare service within the hospital market. This is not only because of changing nature of Indian patient population but also due to the booming medical tourism that India is currently catering to. As a result of these, the sector is attracting good amount of foreign investments or foreign hospital chains establishing business in the country. The Indian government is also undertaking numerous initiatives including tax incentives and budget allocations that would aid in investment inflow and betterment of the market.

Indian entrepreneurs are bringing in innovation within the hospital business by revolutionizing the approach towards healthcare delivery. Initiatives are being taken to penetrate smaller cities and towns where the private sector was hesitant to penetrate even a few years back. Primary and secondary care is being offered through specialty clinics or smaller hospitals specializing in few key areas to reduce their cost of operation yet increase revenue by carrying out more number of the selected few procedures. On the other hand, mobile hospitals and telemedicine is being popularized to reach patient population in rural and urban slum areas for delivering immediate healthcare services.

The Indian competitive landscape of the hospital market is primarily segmented into public and private. The public hospitals operating in the country provide service at a subsidized rate that enables the under privileged access reliable treatment. However, in the private segment hospital business in India is dominated by 11 key players Apollo Hospitals Enterprise Ltd., Fortis Healthcare (India) Ltd., Care Hospitals Pvt. Ltd., Columbia Asia Hospital Pvt. Ltd., Manipal Health Enterprises Pvt. Ltd., Max Healthcare Institute Ltd., Narayana Healthcare Pvt. Ltd., Sankara Nethralaya Pvt. Ltd., Vasan Healthcare Pvt. Ltd., Vaatsalya Health Care Solutions Pvt. Ltd., Wockhardt Hospitals Ltd. that operate as a chain of hospitals, either regionally or nationally while other leading hospitals operate in the standalone format. With the penetration of private sector into the market, healthcare delivery is becoming intensively competitive among the private players which in turn are resulting in constant development in terms of service offered by them.

In addition to covering the Macro Economic Indicators, Indian Healthcare Scenario, Introduction, Market Overview, Drivers & Challenges, IT Adoption, Role of Government, Key Trends, Key Initiatives, Competitive Landscape, Trade Fairs & Events, Recent Transactions, the report also presents strategic insights for the Hospital Market in India. For more information visit: Hospital Market in India 2013

Browse more: Healthcare Market Research Reports

EpiCast Report: Pancreatic Cancer - Epidemiology Forecast to 2022

Pancreatic cancer is one of the most fatal cancers around the world, with the highest incidence and mortality rates found in developed countries (Michaud, 2004). This report provides an overview of the risk factors and the global and historical epidemiological trends for pancreatic cancer in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiology forecast of the incident cases of pancreatic cancer segmented by sex, age (in five-year increments beginning at 15 years and ending at ≥85 years), stage at diagnosis, the proportion of incident cases that undergo resection, locally-advanced unresectable cases, metastatic cases, and biomarker mutation type (KRAS and HER2) in these markets, along with the prevalent cases. For more information visit: EpiCast Report: Pancreatic Cancer - Epidemiology Forecast to 2022

The risk of developing pancreatic cancer is associated with increasing age, as more than 75% of pancreatic cancer patients are over the age of 60 years (SEER Cancer Statistics Review, 2012). Tobacco smoking is one of the most common risk factors for pancreatic cancer, as smokers have a two-fold increased risk of developing the disease compared with nonsmokers (Lowenfels and Maisonneuve, 2006). Due to the short survival period and high mortality for pancreatic cancer, patients with the disease are less likely to suffer from comorbidities than patients with other types of cancer.

North America and western Europe have the highest incidence of pancreatic cancer compared with the rest of the world. The fatal nature of pancreatic cancer keeps the survival rates low and the duration of illness short. The low survival rate associated with pancreatic cancer is caused by the complexity of the disease, along with diagnosis usually occurring during the advanced stages, as the early symptoms typically go unnoticed. In the US, the five-year survival rate of pancreatic cancer is 4.8%, while the 10-year survival rate is only 3.6%; these survival rates showcase that the majority of pancreatic cancer mortality occurs within the first five years of diagnosis (Ries et al., 2007).

This report forecasts that the US and Germany will have the highest number of incident cases of pancreatic cancer in 2022, with 53,610 and 27,629 cases, respectively. It is also expected that the number of prevalent cases of pancreatic cancer in the 6MM covered will increase during the forecast period (2012–2022) to a total of 59,675 cases. The stage at diagnosis for pancreatic cancer is correlated with the availability of screening tests and the ability to identify early symptoms. Due to the inability to identify early indications of the illness, pancreatic cancer cases are most commonly diagnosed in Stage IV. Greater research in prevention and early diagnostic testing can help reduce the incidence of the disease. Through early detection, it may be possible to stop the spread of the cancer to other organs and decrease the overall mortality.

Spanning over 47 pages, 20 tables and figures, “EpiCast Report: Pancreatic Cancer - Epidemiology Forecast to 2022” report presents an in-depth assessment of the global pancreatic cancer epidemiology market till 2022.

In addition to covering the market overview, epidemiology, global trends and key countries the report also presents comprehensive forecasts for the market till 2022.

Browse more Healthcare Market Research Reports

Chronic Obstructive Pulmonary Disease (COPD) Market – A $15.6 Billion Opportunity

                              

The global COPD market is estimated to currently be worth $11.3 billion, and is forecast to reach a value of $15.6 billion by 2019. Much of this growth will be fuelled by a high number of new, more efficacious and convenient products entering the market and commanding greater value compared to the therapies already in the market. The drugs driving this growth include once-daily LABA/LAMA fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium. For more information visit: Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth

Despite recent patent expirations, including that of Advair Diskus (salmeterol/fluticasone propionate), a market leader, generic erosion in the COPD market may not be as pronounced as that observed in other indications. This is largely down to the difficulty in replicating a fixed-dose combination therapy and the associated device. Indeed, since the US patent expired in 2010, Advair Diskus has faced little generic competition

Although the COPD market is characterized by low diagnosis rates, campaigns to increase awareness of the disease in both patients and physicians has resulted in steadily rising diagnosis of COPD. Therefore, this has also contributed to market growth throughout the forecast period.

Spanning over 90 pages, 17 tables and 32 figures, “Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth” report presents an in-depth assessment of the global chronic obstructive pulmonary disease (COPD) market till 2019.

In addition to covering the market overview, marketed product and strategic insights the report also presents comprehensive forecasts for the market till 2019.

To browse more healthcare market research reports visit: Healthcare Market Research Reports

Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline

Pain is a widespread problem across the world. More than 25% of the total population suffers from some clinically significant pain in a year. Since pain considerably affects day-to-day activities in life, its management presents a considerable challenge for physicians. Inadequate pain control remains a major problem across the world. There is an urgent and unmet need to manage these pain-related problems accurately. Currently, the management of pain is not efficient due to low diagnosis and prescription rates. In many cases, such as cancer pain, 50% of the people taking medicines are not satisfied with the results. This is primarily due to the absence of a perfect pain management solution. For more information visit: Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline

Pain management can be most effective only when the underlying disease conditions are cured. However, there is no treatment that offers absolute relief for the indications covered in this report. The medications given for these indications are more for modifying the disease symptoms than offering complete relief from pain. The combination of under-managed pain, low awareness, and fear of addiction to some classes of pain medication is preventing people suffering pain from seeking treatment 100% of the time.

Spanning over 186 pages, 94 tables and 85 figures, “Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline” report presents an in-depth assessment of the global pain management therapeutics market till 2019.

In addition to covering the market overview, market landscape, key geographies like Asia Pacific and China, competitive landscape and strategic insights the report also presents comprehensive forecasts for the market till 2019. The report covers 7 key industry players namely Pfizer Inc, Johnson & Johnson, Endo Pharmaceuticals, Forest Laboratories, Eli Lilly, Teva Pharmaceuticals (Cephalon, Inc.) and Purdue Pharma.

To browse more therapeutic market research reports visit: Therapeutic Market Research Reports

HbA1c Testing Market in India 2013

                 

India is characterized by the presence of a large diabetic population. The country’s status as the diabetes capital of the world has made the need for diabetes prevention and screening very important. Naturally, tests for measuring the blood glucose levels are highly demanded within the country. HbA1c testing in India is also benefiting from this trend. The ability to measure one’s blood glucose levels over a period of 3 months has made it a test favored by many diabetics as well as people who believe they are at high risk of developing diabetes. The market for HbA1c testing has been growing steadily and with the awareness level regarding it increasing rapidly, the market is set to boom in a few years.

For more information visit: HbA1c Testing Market in India 2013

Although the test is considered to be very useful for diabetes screening as well as monitoring the diabetes status of a patient, its much higher cost compared to a simple blood sugar level test can act as a hindrance to its greater acceptance. However, the need to go for HbA1c tests only 3-4 times a year unlike the blood sugar level test which may have to be done on a monthly basis may work in favour of the former. Moreover, HbA1c tests give a clearer picture of the diabetes status of a patient as it a measurement of the glucose levels over a period of 3 months. Several physicians also prescribe this test to their patients which in turn will increase its demand and thereby drive growth in the market.

Several large diagnostic chains offer these tests in India. Majority of the patients going for this test are confirmed diabetics while very few non-diabetics go for this test. Most of the patients visiting laboratories for HbA1c tests have been prescribed to go for the test by a physician with very few people opting for the test on their own. But with increasing awareness among people, this ratio is likely to change and many more people are expected to go for the test independently.

Spanning over 130 pages, “HbA1c Testing Market in India 2013” report presents an in-depth assessment of the HbA1c testing market in India till 2017.

In addition to covering the market overview, drivers and challenges, diabetes disease trends, technology trends, competitive landscape and strategic recommendations the report also presents comprehensive forecasts for the market till 2017. The report covers 15 key industry players namely Abbott India Ltd., Axis-Shield plc, Siemens Ltd., Tosoh Corporation, Apollo Health and Life Styles Ltd., Dr Lal Pathlabs Pvt.  Ltd., Metropolis Healthcare Ltd., Quest Diagnostics India Pvt. Ltd., S Serum Analysis Centre Pvt. Ltd., SRL Diagnostics Pvt. Ltd., Thyrocare Diagnostics Pvt. Ltd., Bayer Pharmaceuticals Pvt. Ltd., Beckman Coulter India Pvt. Ltd., Bio-Rad Laboratories (India) Pvt. Ltd., Transasia Bio-medicals Ltd., Trivitron Healthcare Pvt. Ltd.

To browse more healthcare and diagnostics market research reports visit:

http://www.marketresearchreports.com/diagnostics

http://www.marketresearchreports.com/healthcare

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Germany

Pharmaceutical market in Germany is expected to reach approximately $65.6 billion by 2020 at 3.3% Compound Annual Growth Rate (CAGR). Valued at $51.5 in 2012, with the population of 82 million and growing, the progression of value is expected to be significant in the pharmaceutical market. The Medical device market was worth approximately $22.1 billion in 2012; it is expected to reach approximately $32.6 billion by 2020 at CAGR 5%, reveals new report.

This report provides insights into the demographic, reimbursement and regulatory landscape, healthcare infrastructure and key trends in the healthcare market, along with insights into the trends and segmentation of the pharmaceutical and medical devices markets. This report is built to provide essential source of information by using informed data, information source from proprietary databases, secondary research and in-house analysis.

Spanning over 323 pages, 115 tables and 105 figures, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Germany”, report helps in enhancing decision making capabilities following carefully developing business strategies by understanding German Healthcare industry, to formulate effective sales and marketing strategies by understanding performance of various competitors, and capitalizing on the opportunities and challenges in the German healthcare market.

In addition to the insightful review of the reimbursement and regulatory landscape, the report also covers profiles and SWOT analyses of the major players in the pharmaceutical market, namely Pfizer, Abbott, F. Hoffmann-La Roche, Novartis, and GlaxoSmithKline (GSK); and medical device market, namely Siemens Healthcare, F. Hoffmann-La Roche, Abbott, B. Braun Melsungen and Medtronic.

PharmaPoint: Meningococcal Vaccines - United Kingdom Drug Forecast and Market Analysis to 2022

United Kingdom’s Drug forecast foresees a spectacular growth during 2011-2022. The launch of Serotype B vaccine has brought the critical unmet need in the treatment of Meningococcal disease to a better aid. As the acute infection’s rapid onset and severity of symptoms’ diagnosis is highly difficult, vaccines play a vital role in fighting of the disease caused by the gram-negative bacterium Neisseria meningitidis The tetravalent conjugate vaccines such as Sanofi’s Menactra and Novartis’ Menveo, accounted for major sales and growth of Meningococcal vaccines will be driven by Serotype B vaccines until the launch of Serotype B vaccines.

Patient share for 3 MenC conjugate vaccines will shift due to changes made to the UK MenC schedule (DOH, 2013b). Menjugate and NeisVac-C are expected to be combination of prescription for patients after elimination of single primary dose of Meningitec.

Spanning over 129 pages, 37 tables and 4 figures, PharmaPoint: Meningococcal Vaccines - United Kingdom Drug Forecast and Market Analysis to 2022  report addresses important factors such as Overview of Meningococcal Vaccines, safety and efficacy profiles as well as a SWOT analysis of companies in United Kindom and Sales forecast for the top drugs in the UK from 2012-2022.

PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022

In vaccine dominated space for the treatment of Meningococcal disease, Meningococcal vaccines market foresees a spectacular growth during 2011-2022. MenB vaccine market is expected to grow at a rapid pace during the 10 years period. With adolescents being the target, Pfizer is anticipated to be in rapid uptake, given the ACIP’s current immunization recommendations (CDC, 2013b). As the MenACWY share is predicted to remain stagnant, MenB appears poised to take off in the US, reveals the report.

With the launch of Serotype B vaccine, a critical unmet need in the treatment of Meningococcal disease is expected to be shared with tetravalent conjugate vaccines such as Sanofi’s Menactra and Novartis’ Menveo. As the acute infection’s rapid onset and severity of symptoms’ diagnosis is highly difficult, vaccines play a key role in fighting of the disease caused by the gram-negative bacterium Neisseria meningitidis.

Spanning over 119 pages, 34 tables and 3 figures, “PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022” report addresses key factors such as analysis of the impact of key events, understanding and capitalizing by identifying products that are most likely to ensure a robust return, opportunities and improvements, understanding of the changing competitive landscape, planning your M&A and partnership strategies and sales forecast for the top drugs in the US from 2012-2022.

Browse more Pharma and Healthcare Market Research Reports

MarketResearchReports.com: Oxygen & Portable Oxygen Concentrators (POC) Market - A $1.9 Billion Opportunity, Reveals New Research Report

Global Oxygen & Portable Oxygen Concentrators (POC) market is expected to reach $1.9 billion by 2019, from $242.5 million in 2012, according to a new market research report. This growth is a result of new competitors in the market, demand for the smaller lighter technology by patients, and the market need by for greater mobility support for older people. Older people develop COPD and other respiratory conditions where oxygen is able to improve the quality of the life in a dramatic manner.

In current competitive bidding markets, reimbursement for oxygen is down by up to a third. Providers in these markets are compensating for this reduction by moving their oxygen business to a non-delivery model. The market for oxygen concentrators is being disrupted by the portable devices that can be used to provide oxygen under all circumstances. The reimbursement is too low to support what worked in the past. This is a dramatic shift in the home medical oxygen market.

Spanning over 572 pages and 241 tables & figures, “Oxygen Concentrators: Market Shares, Strategy, and Forecasts, Worldwide, 2013 to 2019” and over 464 pages and 187 tables & figures, “Portable Oxygen Concentrators: Market Shares, Strategies, and Forecasts, Worldwide, 2013 to 2019” reports presents an in-depth assessment of the global oxygen concentrators market from 2013 till 2019.

In addition to covering the business models, market dynamics, technology, key players, the report also presents comprehensive forecasts for the market from 2013 till 2019. The report covers key industry players including Inogen, Longfian, Nidek, Philips Respironics, Invacare, Drive, Chart / Caire / SeQual, Scitech Devilbiss, Teijin, AirSep, O2Concepts Oxlife, Air Liquide, Braun and Company, CareFusion / Intermed Equipment, Chart Industries, CAIRE / SeQual Technologies, Covidien, DeVilbiss Healthcare, Dräger, Drive Medical, Fanem, Fisher & Paykel Healthcare, Gardner Denver / Thomas Compressors, GE Healthcare, Getinge Group AB / Maquet, Graham Field, Hamilton Medical, Heinen & Loewenstein GmbH & Co., Inova Labs, Jiuxin Medical, Leistung Engineering, Longfian Scitech, Merits, Nidek Medical, O2 Concepts, OSI Systems, ResMed, Smiths Group plc / Smiths Medical, Teleflex Incorporated / Teleflex Medical, Terumo, UltraNebs, VBox Trooper, Vitality, Medical, Vygon.

For more information visit:

Oxygen Concentrators: Market Shares, Strategies, and Forecasts, Worldwide, 2013 to 2019 

And 

Portable Oxygen Concentrators: Market Shares, Strategies, and Forecasts, Worldwide, 2013 to 2019

PharmaFocus: Biomarkers in Alzheimer’s Disease

                    

Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. The disease has emerged as a major global health priority especially because of its rapidly accelerating prevalence worldwide. In order to tackle the AD scourge, there is an urgent need for tools that will allow for the early and accurate diagnosis of AD, as well as the identification of populations at risk. A biomarker is an indicator of biological processes that can be objectively measured and evaluated, and well-validated biomarkers are required to satisfy these needs in AD.

Spanning over 179 pages and 59 tables and 10 figures, “PharmaFocus: Biomarkers in Alzheimer’s Disease” report shows drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the AD biomarker market in future. 

The search for biomarkers that are reflective of the disease process in AD has been and continues to be an active area of research, but has been hampered by a lack of clear understanding of the pathological mechanisms that underlie the disease. Nonetheless, several biomarkers have been developed to date that indicate the presence of AD pathology and AD-associated neuronal injury in vivo. Such biomarkers have the potential for clinical use in etiological determination, predictive prognosis, monitoring disease progression, and in clinical trials of potential disease-modifying therapies for AD.

Key Findings

• Amyloid-based biomarkers, and in particular, amyloid PET ligands, are the furthest developed biomarkers for AD and although they have immense value in diagnosis and drug discovery, there is a remaining need for biomarkers of other pathological processes.
• There is a great need for simple inexpensive biomarker assays that can be implement as diagnostic screens for AD and there are numerous blood-based biomarker assays in pipeline aiming to target this need.
• Government regulation will play a major role in biomarker development, clinical market access and use in drug discovery both in the US and in the EU. both in the US and in the EU.

Scope

• Overview of Alzheimer's disease, including disease etiology and pathophysiology and how these inform biomarker targets.
• Overview of AD biomarkers, the major classes of biomarkers an the different potential roles of biomarkers in clinical use and drug development.
• Key topics covered include amyloid biomarkers, tau biomarkers, and other molecular biomarkers for AD in development with product profiles for marketed as well as promising pipeline assays. Also discussed are functional and structural imaging biomarkers for AD.
• Analysis of the unmet needs, and opportunities within the AD biomarker arena, as well as drivers and barriers impacting the AD biomarker market.
• Insightful review of the regulatory considerations impacting biomarker development, market access and use in clinical drug development

Browse more: Pharma and Healthcare Market Research Reports

Country Focus: Healthcare, Regulatory and Reimbursement Landscape - Japan

                

The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Japan. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by publisher team of industry experts.

For more information, visit : CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Japan

In 2012, Japan’s population was estimated at 127.5 million. It is however decreasing due to a negative balance between the birth rate and the mortality rate, as well as a drop in the number of women of child-bearing age, a falling fertility rate, and a low net immigration rate. This may lead to social instability and could pose a threat to economic growth by reducing the availability of a young workforce and increasing the care burden posed by the elderly population. Japan’s pharmaceutical market was estimated to be worth $89.1 billion in 2012 and is expected to reach approximately $104.5 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2%. The medical device market was worth approximately $46.8 billion in 2012 and is expected to reach approximately $73.9 billion by 2020 at a projected CAGR of 6%.

The report provides information on the healthcare, regulatory, and reimbursement landscape in Japan, and includes-

• An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
• Profiles and SWOT analyses of the major players in the pharmaceutical market (Takeda Pharmaceutical, Otsuka Holdings, Astellas Pharma, Daiichi Sankyo, and Eisai) and the medical device market (Hoya Corporation, Medtronic, Abbott Laboratories, F. Hoffmann-La Roche, and GlaxoSmithKline)
• Insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
• Detailed analysis of the political and economic environment, covering economic indicators, demographics, healthcare infrastructure and healthcare expenditure
• An overview of the opportunities for and challenges to growth in the Japanese healthcare market

This report will enhance your decision-making capability by allowing you to–

• Develop business strategies by understanding the trends shaping and driving Japan’s healthcare market
• Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
• Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership
• Identify, understand, and capitalize on the opportunities and challenges in Japan’s healthcare market 

Browse more : Pharma & Healthcare Market Research Reports

Femtosecond Lasers for Cataract Surgery: Market Shares, Strategies, and Forecasts, Worldwide, Nanotechnology, 2013 to 2018

               

The aging of the baby boomers, that is people older than 65 years consume 10 times the eye care of patients that are younger than 65. Due to the soaring population of people older than 65, Ophthalmologists are facing an explosion in demand for their services, such as cataract surgeries for the next 20 years. As the two accommodating Intraocular Lens (IOL) is likely to be approved within the next 12 months, the premium market is exciting.

For more information, visit: Femtosecond Lasers for Cataract Surgery: Market Shares, Strategies, and Forecasts, Worldwide, Nanotechnology, 2013 to 2018

Cataract surgery is the removal of the natural lens of the eye that has developed an opacification, a form of clouding inside the lens which is referred to as a cataract in medical terms. Alcon LenSx Femtosecond Laser technology, a cataract surgical system, makes it possible to deliver reproducible, predictable, and improved clinical outcomes for cataract surgery. Laser assisted cataract surgery is gaining traction with clinicians. Surgeons are getting trained in the techniques needed to perform using the new type of equipment. Cataract procedures for eye care have improved in precision and accuracy since Femtosecond laser-assisted surgery is introduced. Patient population have significant demand for improved vision as they age. Although, people older than 65 years have maintained their lifestyle with the help of good nutritional diet and health clubs, growing needs for good vision remain constant and has created a significant new market for multifocal and laser surgeries.

Safety of Cataract surgical medical devices and lenses are primarily market concern. Lower costs per surgery are driving an increase in cataract surgery, shows the study conducted by WinterGreen Research.

Spanning over 301 pages and 73 tables and figures, “Femtosecond Lasers for Cataract Surgery Market Shares, Strategy, and Forecasts, Worldwide, Nanotechnology 2013 to 2018” report shows the study which includes topics such as, Femtosecond Lasers for Cataract surgery market description and market dynamics, market shares and forecasts, technology, company description and analysis of causes, and benefits of cataract surgery.

In addition to covering industry growth and opportunities for new entrants, this study also covers 13 key players that have had a global presence in scientific research and development of ophthalmology and medical devices related to it, namely Alcon (subsidiary of Novartis), Abbott, AISIN / IMRA Femtolite F / H Family, Bioptigen, Biovision, Calmar Laser, Ophtec Artisan R, OptiMedica, Raydiance, Staar Surgical, Valeant / Bausch & Lomb, WaveTec Vision, and Zeiss.

Browse for more Medical Devices Market Research Reports

Global Medical Devices Market – BRIC and Eastern Europe to Offer More Growth Opportunities Reveals New Research Report

The projected average size of the global annual marketing budget for supplier companies in the medical devices industry in 2012 was US$1.7 million, but this decreased to US$725,000 in 2013, according to a new report from publisher. This decrease was due to market uncertainty, responding to pricing pressure', and regulatory change in global medical devices industry.

According to this survey report, China, India, Brazil, Russia, and Eastern Europe are expected to offer the most industry growth opportunities in 2013. Online content sites and portals were highlighted as a key investment area by 37% of supplier respondents, while 35% of respondents projected strong investment growth in corporate and brand websites. Overall, competitor and market intelligence research, customer intelligence and analytics, and business performance management solutions were identified as the marketing and sales solutions that most respondents expected to invest in during 2013.

Spanning over 142 pages and 60 tables & 58 figures, “Global Medical Devices Survey 2013-2014 - Market Trends, Marketing Spend and Sales Strategies in the Global Medical Devices Industry” report analyzes how medical devices industry supplier companies' media spend, marketing and sales strategies and practices, and business planning are set to change in 2013-2014.

In addition to covering the industry dynamics, growth outlook, threats and opportunities, suppliers' marketing expenditure activity, marketing and sales behaviors and strategies, the report also covers 44 key players in the global medical devices market including Johnson and Johnson, TriStar Wellness Solutions, HemCon Medical Technologies, Digirad, Medtronic, Cordis Corporation, ET View Medical Ltd., Vancive Medical Technologies, Covidien, Biosensors International Group, Spectrum Dynamics, Stryker Inc., Trauson Holding, Bayer, Conceptus, Solta Medical, Sound Surgical Technologies, EndoChoice, Peer Medical, Samsung Electronics America, NeuroLogica, STAT-Diagnostica, High edge consulting, Baxter International Inc., Mikrotech, GE Healthcare, Hemobrás, BPL Medical Technologies, Clearbridge Biomedics, Cambridge consultants, Biomedical Catalyst, Biosense Technologies, Sorin Group, Lab21, IntegraGen, BD Medical, Health Canada, CellAegis Devices, Zoll Medical, BASF, DDA Medical, Eurocom Healthcare Communications, Dudnyk, Dailey Marketing Group.

To browse more medical devices market research reports visit: Medical Devices Market Research Reports

About Market Research Reports, Inc.

Market Research Reports, Inc. (www.MarketResearchReports.com) is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Taiwan Pharmaceutical Market Outlook 2013

#Taiwan Pharmaceutical Market Outlook 2013 New #Report Launched http://t.co/k1u7f3NWOs #Pharma #Market pic.twitter.com/itKXg5CbUD

— MarketResearchReport (@MyMarketReports) July 1, 2013